The Application segmentation of the ONH Combined Analyzer market is organized into three primary end‑use categories: Glaucoma Diagnosis, Neuro‑ophthalmic Research, and Screening Programs. Glaucoma Diagnosis dominates the market, accounting for roughly 55% of total sales, as clinicians rely on detailed optic nerve head metrics to detect early disease progression and guide therapeutic decisions. Neuro‑ophthalmic Research, representing about 30% of the market, utilizes the analyzers for longitudinal studies of optic nerve pathology, driving demand for advanced analytics and data integration capabilities. Screening Programs, which comprise the remaining 15%, focus on large‑scale population health initiatives where speed, portability, and cost‑effectiveness are paramount. This application‑driven taxonomy clarifies how each segment contributes to overall market dynamics, informing strategic investment and product development decisions within the ONH Combined Analyzer segmentation framework.